The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 4, 2015, Pages 239-244

  Sullivan, Harold C ^a   Fisher, Kevin E ^a   Hoffa, Anne L ^a   Wang, Jason ^a   Saxe, Debra ^a   Siddiqui, Momin T ^a   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenocarcinoma; EML4 ALK; fluorescence in situ hybridization; immunohistochemistry; lung

Indexed keywords

MONOCLONAL ANTIBODY; CANCER ANTIBODY; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CARCINOMA; COST BENEFIT ANALYSIS; CYTOPATHOLOGY; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; MAJOR CLINICAL STUDY; NEUROENDOCRINE CARCINOMA; NON SMALL CELL LUNG CANCER; POORLY DIFFERENTIATED CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; CHEMISTRY; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; PATHOLOGY;

ANTIBODIES, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; ONCOGENE PROTEINS, FUSION; SENSITIVITY AND SPECIFICITY;

EID: 84928295357     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000088     Document Type: Article

References (28)

1. Vasikova A. EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy. Klin Onkol. 2012;25:434-439.
2. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010;11:1477-1490.
3. Lee HY, Ahn HK, Jeong JY, et al. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive nonsmall-cell lung cancer. Lung Cancer. 2013;79:40-45.
4. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14:6618-6624.
5. Soda M, Isobe K, Inoue A, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012;18:5682-5689.
6. Carletta J. Assessing agreement on classification tasks: the kappa statistic. Comput Linguist. 1996;22:249-254.
7. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
8. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley; 1981.
9. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51.
10. Savic S, Bode B, Diebold J, et al. Detection of ALK-positive nonsmall-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol. 2013;8: 1004-1011.
11. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545-1553.
12. "Novocastra ALK." Available at: http://www.leicabiosystems.com/ihc-ish/novocastra-reagents/primary-antibodies/details/product/alk-1/. Accessed September 25, 2013.
13. "Anti-ALK antibody [5A4] (ab17127)." Antibodies, proteins, kits and reagents for life science. Available at: http://www.abcam.com/alk-antibody-5a4-ab17127.html. Accessed September 25, 2013.
14. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7:348-354.
15. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77:288-292.
16. Sanders HR, Li HR, Bruey JM, et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet. 2011;204:45-52.
17. Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med. 2012;136:796-803.
18. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415-453.
19. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
20. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275-4283.
21. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723-1733.
22. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174:661-670.
23. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40:1152-1158.
24. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-4253.
25. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10:298-302.
26. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13-17.
27. Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008;61:163-169.
28. Takamochi K, Takeuchi K, Hayashi T, et al. A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One. 2013;8:e69794.